As congressional lawmakers have spent time seeking solutions to the country's opioid epidemic, the US FDA has granted approval to Flexion Therapeutics Inc.'s non-opioid pain medication Zilretta (triamcinolone acetonide extended-release injectable suspension) for the treatment of osteoarthritis-related knee pain.
Several companies made announcements about the use of expedited development and review pathways. Seattle Genetics Inc. and Acadia...








